Singapore launches Phase III of National Precision Medicine Programme

The initiative will focus on those receiving medical treatments and clinical services.

Precision Health Research, Singapore (PRECISE) has launched Phase III of the National Precision Medicine programme to study how genomic information can be used effectively in healthcare.

The initiative will focus on individuals receiving medical treatments and clinical services, including those with specific disease conditions, said Patrick Tan, Executive Director of PRECISE.

The programme follows Phase I, which studied the genomes of 10,000 Singaporeans, and Phase II, under the PRECISE-SG100K initiative, which mapped the DNA of 100,000 people to advance population health research.

“Phase III is about understanding and addressing the practical challenges of integrating precision medicine into clinical care in a thoughtful, sustainable, and equitable way,” Tan added.

The launch was marked by a memorandum of understanding signed with senior representatives from NHG Health, the National University Health System and SingHealth.